Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize

Riyadh, Saudi Arabia, Jan. 07, 2026 (GLOBE NEWSWIRE) — Professor Svetlana Mojsov was announced this year's King Faisal Prize in Medicine laureate for her groundbreaking discoveries that are reshaping how we treat obesity, and Professor Carlos Kenig was announced this year's King Faisal Prize in Science laureate in the field of Mathematics for revolutionizing our […]

Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson’s disease

(Nasdaq First North Finland:HRTIS), Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker data show that HER-096 modulates Parkinson's disease-relevant pathways, consistent with preclinical data, and supporting further clinical development HER-096 exposure was associated with

Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize

Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize Professor Svetlana Mojsov and Professor Carlos Kenig, among other eminent figures, were selected to win the 48th session of the Prize GlobeNewswire January 07, 2026 Riyadh, Saudi Arabia, Jan. 07, 2026 (GLOBE NEWSWIRE) — Professor Svetlana Mojsov was announced this

Pomerantz LLP Informs Investors of Securities Class Action Filing Against F5, Inc. – FFIV

NEW YORK CITY, NY / ACCESS Newswire / January 7, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against F5, Inc. ("F5" or the "Company") (NASDAQ:FFIV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson’s disease

Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease GlobeNewswire January 07, 2026 Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker data show

Pomerantz LLP Advises of Securities Class Action Against agilon health, inc. – AGL

NEW YORK CITY, NY / ACCESS Newswire / January 7, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Agilon Health, Inc. ("Agilon" or the "Company") (NYSE:AGL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

Pomerantz LLP Advises Investors of Class Action Involving Smartsheet Inc. – SMAR

NEW YORK CITY, NY / ACCESS Newswire / January 7, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Smartsheet Inc. ("Smartsheet" or the "Company") (NYSE:SMAR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

Pomerantz LLP Shares Class Action Details With Shareholders in Perrigo Company plc – PRGO

NEW YORK CITY, NY / ACCESS Newswire / January 7, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" or the "Company") (NYSE:PRGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

Pomerantz LLP Reminds Investors: Securities Lawsuit Has Been Filed Against Freeport-McMoran Inc. – FCX

NEW YORK CITY, NY / ACCESS Newswire / January 7, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Freeport-McMoran Inc. ("Freeport" or the "Company") (NYSE:FCX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

SI The Party Presented by DraftKings Returns as One of Big Game Weekend’s 2026 Premier Parties

Featuring headlining performances by The Chainsmokers, Ludacris, DJ Irie & Xandra. The premium celebration for athletes, A-list celebrities, and fans at San Francisco’s iconic Cow Palace SAN FRANCISCO, CA / ACCESS Newswire / January 7, 2026 / Sports Illustrated is thrilled to announce the return of SI The Party Presented by DraftKings during Big Game

Scroll to Top